PIR and fibrosarcoma: To investigate the role of piR-39980/CYP1A2 in modulating chemoresistance in fibrosarcoma, we performed an MTT assay and found that the cell viability of the DOX-treated cell was increased by 40% upon CYP1A2 overexpression (P < 0.05, Fig. 10b).